Regulators, Industry Agree That Frequent Communication Is Key In Developing Breakthrough, PRIME Therapies
Executive Summary
EU and US FDA regulators and industry share strategies for expediting the development of breakthrough and PRIME therapies.
You may also be interested in...
Hits, Misses & Key Firsts For EMA’s PRIME Scheme
The rate at which investigational drugs were accepted onto the European Medicines Agency’s priority medicines scheme dropped in 2021. Meanwhile, more much-needed treatments that had been developed under the scheme went on to win EU marketing approval.
EMA Tells Companies How To Boost Their Approval Chances Under PRIME
Companies find it challenging when it comes to preparing robust quality data packages for their marketing applications for investigational products that have made it onto the European Medicines Agency’s popular priority medicines scheme.
New Therapeutic Targets & A Rich Year For Approvals: EMA’s PRIME In 2020
Last year saw the number of applications accepted onto the European Medicines Agency’s priority medicines scheme inch up and the notoriously high rejection rate for applications drop.